CAMBRIDGE, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation ...
Explore how next-generation analytical methods empower researchers with accurate, consistent AAV titer measurement for gene ...
Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...
AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.
HOUSTON, Sept. 8, 2025 /PRNewswire/ -- AAVivo, Inc., a pioneering biotechnology developing novel, precision targeted biotherapeutics to enable in vivo generation of CAR-T cells, today announced that ...
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apertura Gene Therapy, a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today ...
Platform includes large library of existing capsids, which have been optimized for performance and targeting across a range of application areas through validation in large animal models The addition ...
The AAV9 Total Capsid Quantification Kit incorporates CaptureSelect Anti-AAV9 Biotin and HRP Conjugates for focused quantification of AAV9 particles. Dr Ruizhi Wang, CEO and Founder, Abselion, said: ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback